Don't eat the spinach--controlling foodborne infectious disease.

n engl j med 355;19 www.nejm.org november 9, 2006 1952 including Medtronic’s Endeavor (coated with zotarolimus), Abbott’s Xience V (coated with everolimus), and Conor Medsystem’s CoStar (coated with paclitaxel); however, given the concerns about late stent thrombosis, the FDA could ask companies for longer-term data before considering newer stents for approval in the United States. How long that term should be is likely to be one more contentious issue at the FDA meeting. Meanwhile, as clinicians sort through the new information and await the FDA’s pronouncements, they are already reducing their use of the current technology slightly: sales of drug-coated stents have dipped by 5% for Boston Scientific and 6% for Cordis, while sales of bare-metal stents are edging up.